Publications by authors named "J P Gasnault"
Article Synopsis
- Progressive Multifocal Leukoencephalopathy (PML) is a serious brain disease caused by the JC virus, primarily affecting individuals with weakened immune systems, such as those with AIDS or on strong immunosuppressive drugs like natalizumab for multiple sclerosis.
- A new blood test called the IFN-γ release assay (IGRA) was developed to detect specific immune responses to the JC virus, showing high sensitivity (84%) in active PML patients and very low false positives (3% in healthy individuals).
- The test's results indicate a potential for identifying patients at increased risk of PML, as its positivity rate rises with longer treatment durations on immunosuppressive therapies like natal
Background: Progressive multifocal leukoencephalopathy (PML) is a rare and often lethal brain disorder caused by the common, typically benign polyomavirus 2, also known as JC virus (JCV). In a small percentage of immunosuppressed individuals, JCV is reactivated and infects the brain, causing devastating neurological defects. A wide range of immunosuppressed groups can develop PML, such as patients with: HIV/AIDS, hematological malignancies (e.
View Article and Find Full Text PDFObjective: Our aim was to assess the real-world effectiveness of immune checkpoint inhibitors for treatment of patients with progressive multifocal leukoencephalopathy (PML).
Methods: We conducted a multicenter survey compiling retrospective data from 79 PML patients, including 38 published cases and 41 unpublished cases, who received immune checkpoint inhibitors as add-on to standard of care. One-year follow-up data were analyzed to determine clinical outcomes and safety profile.
Objective: Restoring anti-JC virus (JCV) immunity is the only treatment of progressive multifocal leukoencephalopathy (PML). Interleukin-7 is a cytokine that increases number and function of T cells. We analyzed a population of PML patients who received recombinant human IL-7 (rhIL-7) to estimate survival and its determinants.
View Article and Find Full Text PDFObjectives: The penetration of antiretroviral drugs into deep compartments, such as the CNS, is a crucial component of strategies towards an HIV cure. This study aimed to determine CSF concentrations of bictegravir, emtricitabine and tenofovir in patients with HIV-related CNS impairment (HCI) enrolled in a real-life observational study.
Methods: Patients with HCI treated by optimized ART, including bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) for at least 1 month were enrolled.